You should remember that trials are structured environments
As of now, there are no large-scale clinical trials specifically evaluating semaglutide for RA treatment
Degradation products can sometimes cause additional adverse reactions that the intact peptide would not
For instance, the subcutaneously injected drug Semaglutide 2.4 mg, approved in 2021 and administered once a week, has been shown to achieve an average weight reduction of 15%-17% and also offers cardiovascular protective effects
80C preferred for extended storage Short-term Storage: 28C acceptable in sealed, desiccated vials Room Temperature: During transport only
About why a drug with no approved version anywhere on earth came to be injected by people who measured their doses to the unit, what the laboratories find on the rare occasions anyone tests these products, and why the contaminant in those six Victorian vials was, in a structural sense, always coming